Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16527590 | 1.00 | DGAT1 (0.51) | DGAT1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL16527728 | 0.92 | HTT (0.51) | DGAT1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL16527729 | 0.92 | HTT (0.51) | DGAT1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL16542737 | 0.91 | GCGR (0.50) | DGAT1 | |
| SCHEMBL16527620 | 0.91 | GCGR (0.50) | DGAT1 | |
| SCHEMBL16527741 | 0.90 | DGAT1 (0.53) | DGAT1 | |
| SCHEMBL16527742 | 0.90 | DGAT1 (0.53) | DGAT1 | |
| SCHEMBL10185470 | 0.89 | NPC1 (0.55) | DGAT1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL16527713 | 0.89 | SMN1; SMN2 (0.48) | DGAT1MAPTALDH1A1GAAKMT2A | |
| SCHEMBL16542612 | 0.89 | SMN1; SMN2 (0.48) | DGAT1MAPTALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321728-B2 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-26 | — | — | US | claimed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | claimed |
| EP-2842938-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-03-04 | — | — | EP | claimed |
| US-9321728-B2 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-26 | — | — | US | disclosed |
| CN-104254519-B | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same as the active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-20 | — | — | CN | disclosed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| EP-2842938-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-03-04 | — | — | EP | disclosed |
| CN-104254519-A | Novel beta-alanine derivative, pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | KOREA RES INST CHEM TECH | 2014-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | DGAT1, GOT1, ACAT2 | DGAT1 1/4885MAPT 1954/4885NPC1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.